Fig 1: The autointeraction within TAD activates FOXM1 during the G1/S phase to the late G2 phase. (A) The scheme illustrates the tracking of FOXM1 TAD autointeraction using FRET-based living cell microscopy imaging. The double thymidine block synchronized U2OS stable cells co-expressing FOXM1 fusion proteins CFPTAD insX-FOXM1 and FOXM1-YFP were released for FRET analysis. (B) Representative live-cell FRET images displaying NFRET over time intervals for the untreated cells (upper panel), cells treated with volasertib (middle panel), and cells expressing CFP or YFP fused FOXM1 S715A/S724A mutants (lower panel) after synchronization. (C) The average NFRET fold change at indicated time points showed the increased intermolecular TAD–TAD interaction as cell release from G1/S arrest (upper panel). Average NFRET fold change of the TAD–TAD interaction peak during the S to G2 phase was abolished in the cells treated with volasertib (middle panel) and cells expressing FOXM1 with S715A/S724A mutations (lower panel), compared to the untreated group (upper panel). (D) Flow cytometry analysis of synchronized U2OS cells for cell cycle phase determination. (E) DLR assay assesses FOXM1 activity in U2OS cells that were synchronized and collected at different time points following G1/S release. (F) DLR assay assessed FOXM1 activity in U2OS cells synchronized at the G1/S phase, subsequent to disrupting PLK1 phosphorylation with 7.8 nM volasertib treatment for 6 h. (G) DLR assay determined FOXM1 activity in the synchronized U2OS cells that were co-transfected with FOXM1 harboring S715A/S724A mutations. (H) U2OS cells were co-transfected with ΔN-FOXM1, TAD and reporter plasmids were subjected to DLR assay. (I) USO2 cells co-expressing ΔN-FOXM1 and TAD wild type, S715A/S724A variant or S715D/S724D variant was applied for co-IP assay. NFRET data were collected and analyzed using images from at least five individual cells. The DLR data value represents mean ± s.d. *P< 0.05; **P< 0.01 and ***P< 0.001.
Fig 2: Autoactivation of FOXM1 through TAD and IDR interaction is NRD-independent. (A) A schematic drawing of the human FOXM1b protein containing a well-structured DBD (residues 235–327), two potentially structured regions (residues 51–121 and 696–748), as well as a disordered region (residues 328–584). (B) Computational prediction revealed a highly conserved secondary structure (residues 696–748) in the FOXM1 C-terminus across different species. The extended (‘E’) and helical (‘H’) secondary structures were labeled, and the Jnet_Rel represents Jnet reliability of prediction accuracy, which ranges from 0 to 9. (C) Jpred prediction detected largely disordered regions in the N-terminal region of the TAD (residues 328–584). (D) Expression of TAD stimulates hyperactivation of ΔN-FOXM1. U2OS cells co-expressing ΔN-FOXM1 and truncated TAD fragments were collected to determine FOXM1 activity by DLR assay. (E) The co-IP assay revealed an interaction between the C- and N-terminal region of the TAD. U2OS cells were co-transfected with plasmids expressing mCherry-tagged TAD 696–748 and GFP-tagged TAD N-terminal fragment. Protein–protein interactions were detected through GFP immunoprecipitation followed by mCherry immunoblotting. (F) The proximity interaction between TAD–TAD is induced by a CID system. Plasmids FRBTAD InsX–FOXM1 and FOXM1–FKBP were constructed by inserting FKBP-rapamycin binding protein (FRB) upstream to TAD and FK506 binding protein (FKBP) downstream to TAD C-terminus. U2OS cells transiently co-expressing both were treated with the dimerizing reagent rapamycin and subjected to Native-PAGE and western blotting. Upon rapamycin treatment, the co-expressing cells showed increased levels of FOXM1–FOXM1 dimer (marked with a star), along with a reduction in FOXM1 monomer signal (arrow). In comparison, the 696–748 deletion mutant (Δαβα-FOXM1) did not form dimers (the first lane). (G) The proximity interaction between TAD–TAD, induced by a CID system, significantly enhanced FOXM1 activity. The FOXM1 CID system and reporter expression vectors were co-expressed in U2OS cells, followed by rapamycin treatment. The experiments were performed in triplicate, and the results for each group are represented as mean ± standard deviation (s.d.). *P< 0.05; **P< 0.01 and ***P< 0.001.
Fig 3: The autorepression-driven FOXM1 self-interaction declines after G1/S progression. (A) The schematic illustrates the CFP-FOXM1 and FOXM1-YFP fusion proteins used for FRET analysis. (B) Representative images displaying NFRET in synchronized U2OS cells revealed the NRD–TAD interaction under different conditions. The mitotic parent cells are indicated by arrows, while the daughter cells are indicated by arrowheads. (C) The interaction between NRD and TAD declined during the S to G2 phase, as indicated by the blue line representing the fold change in FOXM1 NRD–TAD intermolecular interaction measured by NFRET (upper panel). Inhibiting PLK1 phosphorylation maintains NRD–TAD interaction after G1/S phases (middle and lower panel). U2OS stable cells, upon treatment with volasertib (middle panel), and those expressing FOXM1 containing the S715A/S724A mutation (lower panel), showed a significantly attenuated decrease in NFRET produced by the NRD–TAD interaction after G1/S phase. NFRET analysis was performed on images from at least five individual cells for each experimental group. (D) The FOXM1 autorepression was mimicked by using the CID system. Cells co-transfected with FRB–FOXM1 (where the FRB domain was fused upstream to NRD) and FOXM1–FKBP plasmids were then treated with rapamycin and analyzed through Native-PAGE and western blot analysis. The addition of a dimerizing reagent enhanced the FOXM1–FOXM1 dimer signal (star) while reducing the presence of FOXM1 monomers (arrow) in co-transfected U2OS cells. Δαβα–FOXM1 mutant displayed no observable dimers under native conditions (first lane). (E) DLR assay results showed decreased FOXM1 activity after rapamycin addition to cells co-transfected with FRB–FOXM1 and FOXM1–FKBP. DLR data was collected in triplicate and represented as mean ± s.d. Statistical significance levels were denoted as *P< 0.05; **P< 0.01; and ***P< 0.001. (F, G) The CID system demonstrated an intramolecular conformational switch in FOXM1. CID and Native-PAGE were conducted by using U2OS cells expressing FRB–FOXM1–FKBP (with FRB fused upstream of NRD and FKBP fused downstream of TAD) as shown in panel (F), or by U2OS cells expressing FRBTAD InsX–FOXM1–FKBP (where FRB was fused upstream of TAD) was shown in (G). The signal pointed by an arrowhead was assumed an intramolecular switch in monomeric FOXM1 that is between dimeric (star) and non-induced monomeric FOXM1 (arrow).
Fig 4: The activation of FOXM1 during the cell cycle is mediated by changes in its homodimerization states. (A, B) FOXM1 binding to human CDC25B promoter regions (−92/+120) was examined in U2OS cells with induced autorepression or autoactivation. Chromatin of U2OS cells co-expressing the FOXM1 CID plasmids was processed through PFA cross-linking, micrococcal nuclease digestion and immunoprecipitation using FOXM1 (A) or GFP (B) antibody. The immunoprecipitated chromatin was analyzed through quantitative RT-PCR. (C, D) The quantitative ChIP assays demonstrated FOXM1 binding to human Survivin promoter regions (−1531/−1373) in response to the CID system. The statistical significance was calculated by unpaired two-tailed Student’s t-test: *P< 0.05; **P< 0.01 and ***P< 0.001. (E) In the early G1 phase, FOXM1 proteins initially undergo repression due to the αβα–ββαβ interaction. Their dimerization occurs through the NRD–TAD proximity. However, the introduction of PLK1 phosphorylation on αβα disrupts this interaction, thereby diminishing autorepressed dimerization as cells progress from the S phase through the G2/M phase. Subsequently, the PLK1-phosphorylated αβα shows a preference for interaction with IDR, facilitating an alternative dimerization of FOXM1 proteins through αβα–IDR proximity. This autoactivation homodimerization significantly enhances FOXM1 activity from the S to G2/M phases.
Fig 5: A minimal functional peptide originating from FOXM1 NRD inhibits cancer cell proliferation and tumor growth. (A, B) The A549 stable cells that were generated through pInducer lentiviral transduction to express FOXM1 NRD 51–121 inducibly with DOX. The vitality of A549 stable cells was assessed by MTT assay over 5 days of DOX-induced expression of NRD 51–121 (B) compared to non-DOX treated cells (A). (C) The MTT assay was performed to assess cell viability in DOX-induced NRD 51–121-expressing stable cells transduced with adenoviral GFP (Ad-GFP) or GFP-FOXM1 (Ad-GFP-FOXM1). (D) qRT-PCR was performed on lysates from the His-NRD 51–121 expressing A549 stable cells to examine levels of CDC25B, anti-apoptosis genes Survivin and SGMS-1(SMS-1). All P-values were less than 0.001 when compared to the non-DOX group. (E, F) Alexa Fluor 647-labeled immunodetection was applied to identify A549 stable cells undergoing apoptosis 48 h after DOX induction for NRD 51–121 expression (E). The percentage of apoptotic cells was determined by dividing the number of TUNEL-positive cells by the total number of DAPI-positive cells (F). (G, H) SA-β-gal staining demonstrated an increase in cellular senescence in A549 stable cells induced by NRD 51–121 after treatment with DOX for 96 h (G). The percentage of SA-β-gal positive cells was determined from a minimum of 10 microscopic views of each sample, which were used for statistical analysis (H). (I) RT-qPCR analysis showed the mRNA levels of CDC25B, Survivin and SGMS-1 in Ad-GFP-FOXM1 transduced A549 cells compared to the Ad-GFP control. (J, K) The TUNEL assay was performed to identify apoptotic cells in A549 stable cells expressing NRD 51-121 and transduced with either Ad-GFP-FOXM1 or Ad-GFP. (L, M) SA-β-gal staining showed a decrease in cellular senescence in DOX-induced A549 stable cells expressing NRD 51-121 and transduced with Ad-GFP-FOXM1, compared to those transduced with Ad-GFP. (N, O) The subcutaneous xenograft mouse model utilized A549 cells transduced with either the NRD 51–121 6A (mutant) or wild-type NRD 51–121. Tumors from A549 cells transduced with NRD 51–121 6A from the left flank (arrowhead) of each mouse were isolated at day 70 (N, lower panel) and sequentially aligned with the corresponding mice (N, upper panel). No tumor tissue was observed in the right flank (arrow) of each nude mouse and was therefore not excised. Tumor diameters were measured twice a week, and the curve of the average tumor volume in each group is shown (O). Data: mean ± s.d. Statistical analysis: unpaired two-tailed Student’s t-test. *P< 0.05; and ***P< 0.001; ns, no significance.
Supplier Page from OriGene Technologies for FOXM1 (NM_202003) Human Untagged Clone